Michael D. Casey

Former Chairman, President & Chief Executive Officer at Matrix Pharmaceutical, Inc.

Michael D. Casey

Michael D. Casey

Former Chairman, President & Chief Executive Officer at Matrix Pharmaceutical, Inc.

Overview
Career Highlights

Genetic Therapy, Inc.
McNeil Pharmaceutical
Matrix Pharmaceutical, Inc.

RelSci Relationships

385

Number of Boards

11

Birthday

1946

Age

72

Relationships
RelSci Relationships are individuals Michael D. Casey likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman of the Board & Chief Executive Officer at Celgene Corp.

Relationship likelihood: Strong

Former Chief Financial Officer & Executive Vice President at Family Restaurants, Inc.

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Kaleido Biosciences, Inc.

Relationship likelihood: Strong

Chief Executive Officer at ABAXIS, Inc.

Relationship likelihood: Strong

Founder & Chairman at Celgene Corp.

Relationship likelihood: Strong

Former Chief Executive Officer at Celgene Corp.

Relationship likelihood: Strong

Director of the Global Health Program for Tuberculosis at Bill & Melinda Gates Foundation

Relationship likelihood: Strong

Venture Partner at Pappas Capital LLC

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Humacyte, Inc.

Relationship likelihood: Strong

Founder at Athenaeum Group

Relationship likelihood: Strong

Paths to Michael D. Casey
Potential Connections via
Relationship Science
You
Michael D. Casey
Former Chairman, President & Chief Executive Officer at Matrix Pharmaceutical, Inc.
Career History
Chairman, President & Chief Executive Officer
1997 - 2002

Part of Novartis AG, Matrix Pharmaceutical, Inc. is an American company located in Fremont, CA, involved in in vitro and in vivo diagnostic substances. The firm was founded by Dennis M. Brown. Matrix Pharmaceutical, Inc. was acquired by Chiron Corp. on 19 Feb 02 for $58.63 million.

President, Retail & Specialty Products Divisions
1995 - 1997
President & Chief Operating Officer
1993 - 1995

Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD.

Boards & Committees
Member, Board of Directors
2010 - Current

ABAXIS, Inc. engages in the development, manufacture, and marketing of portable blood analysis systems. It operates through the following segments: Medical Market, Veterinary Market, and Other. The Medical Market segment serves a customer group consisting of physicians’ office practices across multiple specialties, urgent care, outpatient and walk-in clinics, health screening operations, home care providers, nursing homes, ambulance companies, oncology treatment clinics, dialysis centers, pharmacies, hospital laboratories, military installations, pharmaceutical clinical trials, and cruise ship lines. The Veterinary Market segment focuses on animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies, and private research laboratories. The company was founded by Vladimir E. Ostoich in April 1989 and is headquartered in Union City, CA.

Lead Independent Director
2002 - Current

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Director
Current

Celgene Ltd. develops human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialisation of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company is headquartered in Uxbridge, the United Kingdom.

Political Donations
$250
1996

Chairman at Waxman Strategies

Public Holdings
Restricted data only for RelSci Professional users.